Genmab — Januar 2019
-
970 i morgen? Andre bud?
-
Kursen skal i hvert fald op hvis ikke en eventuel køber skal have Genmab for billigt.
-
-
Det er jo det vi ser allerede i sektoren: "Jefferies healthcare strategist Jared Holtz is a short-term biotech bear saying that profit-taking "makes sense" through this earnings season considering the sector's market-leading performance so far this year"
-
-
Ja, med de briller på kan man godt se det bliver vanskeligt at guide. Men han rammer jo nogle meget vigtige centrale punkter som man mangler svar på. Det flade salg i US er jo ganske givet ikke kun på grund af stole mangel. Men hvad er det så. ? Håber på nogle svar når regnskabet Q 4 kommer . Og de skal helst være gode.
-
hvad var SH tallet??
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind